C-Blu’s Azure Pro provides clinicians in low-resource areas with increased accessibility to and efficacy of cervical cancer screening by making pre-cancerous tissue easier to visually identify. Unlike other colposcopes on the market, C-Blu’s Azure Pro increases efficacy by making pre-cancerous tissue fluoresce and is affordable even in low-resource areas. Cervical cancer can be treated very easily and effectively with early diagnosis. However, a challenge for clinicians in low-resource areas is access to affordable screening methods that still provide accurate results. The World Health Organization (WHO) has a goal to eliminate cervical cancer by 2030. Part of the plan to accomplish this goal is to have 70% of women screened for cervical cancer by 35 years old and again by 45 years old. We are committed to solving this problem.